Johnson & Johnson Innovation Opens JLABS @ Shanghai in Collaboration with Shanghai Pharma Engine Company Ltd.

The world's largest JLABS and the first in Asia Pacific aims to support more than 50 life science start-ups from around the world with the hope to accelerate healthcare innovation in China and globally
Johnson & Johnson Innovation
2019-06-27 19:13 10166

SHANGHAI, June 27, 2019 /PRNewswire/ -- Johnson & Johnson Innovation, Division of Johnson & Johnson (China) Investment Ltd., today announced the opening of JLABS @ Shanghai, the world's largest JLABS and the first in Asia Pacific. The 4,400-square-meter facility, located in Shanghai's Zhangjiang Hi-Tech Park, is a collaboration with the Shanghai Pharma Engine Company, Ltd. JLABS @ Shanghai can accommodate more than 50 start-ups across the pharmaceuticals, medical device, consumer and health tech segments, and opens with 31 resident companies, including the three awardees of the Lung Cancer Innovation QuickFire Challenge.

Opening Ceremony of JLABS@Shanghai, Johnson & Johnson Innovation
Opening Ceremony of JLABS@Shanghai, Johnson & Johnson Innovation

"Johnson & Johnson has deep roots in China with an innovation footprint dating back nearly four decades. We are committed to fueling innovation in the region and unleashing the power of science and technology to advance the health of people in China and around the world," said Paul Stoffels, M.D., Vice Chairman, Executive Committee and Chief Scientific Officer, Johnson & Johnson. "The new JLABS in Shanghai will connect global and local entrepreneurs with the expertise of the Johnson & Johnson Family of Companies and our strategic partners to help transform great ideas into breakthrough solutions."

Speech by Paul Stoffels, M.D., Vice Chairman, Executive Committee and Chief Scientific Officer, Johnson & Johnson
Speech by Paul Stoffels, M.D., Vice Chairman, Executive Committee and Chief Scientific Officer, Johnson & Johnson

At the opening, JLABS @ Shanghai announced the awardees of the Lung Cancer Innovation QuickFire Challenge, which was launched in June 2018 to focus on the prevention, interception and curing of lung cancer. The awardees will receive a total of US$750,000 in grants; one year of residency at JLABS @ Shanghai, including a laboratory bench, workstation and access to the JLABS community; and mentorship and coaching from Johnson & Johnson Innovation. The three awardees are: DNX Biopharmaceuticals, Inc., Hawkeye Bio and NE Scientific LLC.

"The opening of JLABS @ Shanghai couldn't have come at a better time for China and the world, facing the growing challenge of diabetes, cancer, and an aging population. Together we can identify and nurture best in class science to transform how diseases are treated, cured, prevented and intercepted," said Melinda Richter, Global Head, Johnson & Johnson Innovation - JLABS[i]. "We can't do that well for the 1.4 billion people in China without being right here, working hand-in-hand with the right people. Today, all of you, and the companies and entrepreneurs of JLABS @ Shanghai, have the potential to create solutions that can be global answers as we work toward the hope of a world without disease."

"Johnson & Johnson is honored to collaborate with the Shanghai Pharma Engine Company Limited to bring JLABS to Shanghai," said Will Song, Chairman, Johnson & Johnson China and President, Johnson & Johnson Medical China[ii]. "JLABS @ Shanghai adds to our expanding presence of R&D, and innovation centers in Shanghai to develop a regional hub for innovation across the Johnson & Johnson Family of Companies and serves as a key contributor to the government's Healthy China 2030 initiative."

JLABS sites have hosted more than 540 companies to date, advancing several biotech, pharmaceuticals, medical device, consumer and health tech programs. JLABS @ Shanghai will follow the same no-strings-attached approach across all existing JLABS locations: San Diego; San Francisco; Boston; Lowell; Houston; Toronto; Beerse, Belgium; New York City and the newly announced Washington, DC. The following companies are the first to be selected as residents of JLABS @ Shanghai:

JLABS @ Shanghai Resident

About the Company[iii] 

Achelois Pharmaceuticals

Acheloís focuses on the development of T cell medicine
for solid tumor.

Analytics For Life Inc.

Analytics For Life utilizes non-invasive AI machine-
learning solutions to assess and diagnose diseases such
as coronary artery diseases.

Aprinoia Therapeutics

Aprinoia Therapeutics focuses on developing novel
therapeutics and imaging-based diagnostics


AsiaBiome is a platform technology for the discovery
and development of live bio-therapeutic drugs based on
exclusive access to microbiome data and samples in Asia.

Beijing Syngentech

SyngenTech pioneers Synthetic-Biology based live
therapeutics, 'programmed' to harness the immune system
and fight cancers. 

BioSense Suzhou Ltd.

BioSense focuses on discovering novel kinase inhibitors
(KI) based upon the proven functional scaffolds of potent
natural KIs.

Black Ceramic Medical Technology 

Black Ceramic Medical Technology focuses on the
research and development of upmarket silicon nitride
ceramic joint implants.

Bridge Biotherapeutics Inc.

Bridge Biotherapeutics develops therapeutics for the
effective treatment of various autoimmune diseases such
as ulcerative colitis and fibrotic diseases.

ChemSun (Cayman)

ChemSun discovers and develops new innovative next-
generation antibody-based drugs for lung cancer.

Corestone Biosciences

Corestone Biosciences focuses on innovative medical
devices on non-invasive respiratory monitoring and
continuous nerve blocking catheter foracute pain
management in surgery.

DNX Biopharmaceuticals, Inc.

DNX Biopharmaceuticals is developing highly innovative
anti-cytokine therapeutics, including DNX-314 and DNX-
114, addressing unmet medical needs for rare cancers,
non-rare cancers, and IL-1 or TNF-α-mediated Systemic
Autoinflammatory Diseases (SAIDS.).

Hawkeye Bio

Hawkeye Bio provides a non-invasive breath test for the
early detection of lung cancer.

Helios Bioelectronics

Helios Bioelectronics is a semiconductor-based
diagnostic platform with AI and cloud computing

Hepagene Therapeutics (Shanghai), Inc

Hepagene Therapeutics discovers, develops and delivers
innovative medicines that help patients with liver diseases.

HighTide Therapeutics

HighTide Therapeutics focuses on the development of
novel therapeutics for liver, gastrointestinal, and metabolic


Holmusk is a data science and digital therapeutics
company establishing objective evidence as a core utility
to the treatment of mental health and chronic diseases. 

Inertia Biotechnology

Inertia Biotechnology develops a direct-to-consumer skin
test kit to help users understand their skin and choose
suitable skin care routines.

Jiangsu Nuo-Beta Pharmaceutical Technology

Jiangsu Nuo-Beta Pharmaceutical Technology focuses
on treating Alzheimer's Disease by facilitating cellular
release of beta amyloid 42 via inhibition of PI4KIIIa.

Lifespans Limited

Lifespans develops proprietary approaches to making
implants safer and more effective when repairing broken
bones in elderly patients.


LIVE2LIFE develops a cloud
platform DSP@MTUBE and applies AI & blockchain to
index, analyze and exchange all surgical intervention

Maiden Therapeutics

Maiden Therapeutics is developing a drug discovery
platform utilizing the human milk microbiome to discover
drug-like molecules


Metabonose focuses on integrating personalized nutrition
into daily gut microbiota eubiosis management.


mSENSE develops and provides intelligent and
professional health management solutions.

NE Scientific

NE Scientific develops novel surgical guidance software
that helps physicians in achieving significantly improved
outcomes in the ablation of tumors.


Octimet develops a family of selective MET kinase

Santai Biotech

Santai Biotech develops develops tissue engineering
products to repair tissue/organ injury.

Shanghai Tuoxiao Intelligent Technology Co.

Shanghai Tuoxiao Intelligent Technology Co. focuses
on the development of congenital heart disease screening-
related equipment and systems using digital stethoscope
and AI.

SpineGuide Technologies

SpineGuide Technologies is developing an implant for
Idiopathic Scoliosis designed to provide correction and
maintain the growth of the spine at the same time.

Vigor Medical Systems

Vigor Medical Systems is a device and digital health
platform that focuses on diagnosing and managing chronic
respiratory disease.


Xinguang focuses on the treatment of metabolic disorders
such as alcohol poisoning and gout, with a combination of
liposome or chitosan-encapsulated multi-enzymes.

Applications to join JLABS @ Shanghai and other JLABS sites are currently being accepted from biotech, pharmaceutical, medical device, consumer and digital health companies. For more information, visit

About Johnson & Johnson Innovation 

Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses.
Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical,
medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers;
Johnson & Johnson Innovation - JLABS; JJDC, Inc.; and our business development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in
patients. JLABS provides the laboratories, expertise, education, tools and resources needed to help life science startups thrive, all with no strings attached. A Johnson & Johnson Innovation Center for Device
Innovation at the Texas Medical Center (CDI @ TMC) has been established to accelerate the development of medical devices. For more information about Johnson & Johnson Innovation,
please visit:


About Johnson & Johnson Innovation JLABS

Johnson & Johnson Innovation – JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical,
medical device, consumer and health tech sectors to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing
the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing
a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS, we value great ideas and are passionate about
removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while
holding on to their intellectual property. JLABS also produces campaigns to seek out the best science called QuickFire Challenges. For more information, visit or follow @JLABS.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to a new collaboration. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Innovation LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges inherent in new product development, including the uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2018, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. Johnson & Johnson Innovation LLC and Johnson & Johnson do not undertake to update any forward-looking statement as a result of new information or future events or developments.

[i] Johnson & Johnson Innovation LLC

[ii] Johnson & Johnson Medical (Shanghai) Ltd. 

[iii] Descriptions were provided by respective companies


Photo -
Photo -

Source: Johnson & Johnson Innovation